Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:ceo |
gptkb:Yongjun_Wu
gptkb:Dr._Patrick_H._Yang |
| gptkbp:clinical_trial |
Phase 2
Phase 1 trials |
| gptkbp:develops |
therapeutics
|
| gptkbp:focus |
immuno-oncology
|
| gptkbp:focuses_on |
immuno-oncology
|
| gptkbp:founded |
gptkb:2012
gptkb:2021 |
| gptkbp:headquarters |
gptkb:San_Carlos,_California
gptkb:California |
| https://www.w3.org/2000/01/rdf-schema#label |
Apexigen
|
| gptkbp:investment |
gptkb:venture_capital
|
| gptkbp:known_for |
gptkb:APX005_M
|
| gptkbp:partnership |
pharmaceutical companies
|
| gptkbp:partnerships |
pharmaceutical companies
|
| gptkbp:product |
gptkb:APX005_M
|
| gptkbp:technology |
antibody platform
|
| gptkbp:website |
www.apexigen.com
|
| gptkbp:bfsParent |
gptkb:Sanofi
gptkb:Takeda |
| gptkbp:bfsLayer |
4
|